Study of "de novo" XXXX among greek renal transplant recipients.

@entity1 @entity2826 @entity706 @entity5 @entity1489 @entity205
The incidence of @entity5 was estimated in 1055 renal transplant recipients, engrafted between 1983 and 2001 including 611 grafts from living and 444 from cadaveric donors. The meoplasms were 22 @entity1489 , 18 @entity2826 , 10 @entity706 nine non-Hodgkin's and one Hodgkin's lymphoma) and 24 visceral carcinomas. @entity1489 were completely excised. @entity1 with @entity2826 were treated by tapering the immunosuppression with cessation of @entity205 . In addition, four @entity1 received chemotherapy, and one of them received local radiotherapy. All @entity1 with @entity706 were treated by cessation of calcineurin inhibitors with modulation of the immunosuppression to levels that were safe for the graft. Furthermore, five @entity1 underwent first line chemotherapy, two @entity1 radiotherapy and two @entity1 , surgical @entity5 . The @entity1 with @entity5 were treated surgically with excision of the lesions when possible, without severe modification of the immunosuppressive regimen. Chemotherapy or radiotherapy was added accordingly. Disease-related mortality rate in @entity1 with @entity1489 was 4.5%; in @entity2826 cases 11.11%; in @entity706 50%; and in all the other instances, 45.8%. This study shows the increased incidence of certain @entity5 in transplant recipients, illustrating the importance of @entity5 surveillance following kidney transplantation. A substantial reduction or even cessation of immunosuppressive therapy may be necessary to achieve @entity1 survival.
